share_log

CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter

CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter

《華爾街評論》的吉姆·克雷默表示,CVS具有「真正的價值」:美光度過了一個「驚人」的季度
Benzinga ·  10/11 21:06

When asked about CVS Health Corporation (NYSE:CVS) on CNBC's "Mad Money Lightning Round," Jim Cramer said, "I think there's real value here."

當被問及CVS Health Corporation (紐交所:CVS) 在CNBC的"瘋狂金錢閃電輪"節目上,吉姆·克雷默表示:"我認爲這裏有真正的價值。"

On Oct. 10, Barclays analyst Andrew Mok upgraded CVS Health from Equal-Weight to Overweight and raised the price target from $63 to $82.

10月10日,巴克萊銀行分析師安德魯·莫克將CVS Health的評級從Equal-Weight升級爲Overweight,並將價格目標從63美元提高至82美元。

Cramer also recommends buying Micron Technology, Inc. (NASDAQ:MU), saying it had an "amazing" quarter.

克雷默還建議購買美光科技公司 (納斯達克:MU),稱其季度"驚人"。

On Oct. 8, Keybanc analyst John Vinh maintained Micron Technology with an Overweight and lowered the price target from $145 to $135.

10月8日,凱班克分析師約翰·文將美光科技維持爲Overweight,並將價格目標從145美元下調至135美元。

Although Cramer believes Old Dominion Freight Line (NASDAQ:ODFL) will have a good year, but he prefers the stock of Union Pacific (NYSE:UNP).

儘管克雷默認爲Old Dominion Freight Line (納斯達克:ODFL) 將度過一個好年,但他更偏愛聯合太平洋 (紐交所:UNP) 的股票。

On Oct. 9, Citigroup analyst Ariel Rosa initiated coverage on Old Dominion Freight Line with a Neutral rating and announced a price target of $206.

10月9日,花旗集團分析師艾瑞爾·羅莎對Old Dominion Freight Line發起覆蓋,評級爲中立,並宣佈了206美元的價格目標。

The "Mad Money" host recommended not touching American Tower (NYSE:AMT).

《瘋狂金錢》主持人建議不要觸及美國塔架 (紐交所:AMT)。

On Oct. 10, Barclays analyst Tim Long maintained American Tower with an Overweight and raised the price target from $223 to $255.

10月10日,巴克萊銀行分析師蒂姆·朗將美國塔架維持爲Overweight,並將價格目標從223美元上調至255美元。

Cramer said Howmet Aerospace Inc. (NYSE:HWM) is going higher, adding that it is one of the greatest stocks of his time.

克雷默表示howmet aerospace股票(紐交所:HWM)將繼續上漲,並補充說這是他所見過的最好的股票之一。

Howmet Aerospace will announce its third quarter 2024 financial results on Wednesday, Nov. 6.

howmet aerospace將於2024年第三季度業績發佈日週三,11月6日公佈其財務業績。

ADMA Biologics (NASDAQ:ADMA) is a "very speculative" stock, Cramer said.

adma biologics(納斯達克:ADMA)是一隻「很有投機性」的股票,克雷默表示。

On Sept. 20, Cantor Fitzgerald analyst Kristen Kluska reiterated ADMA Biologics with an Overweight and maintained a $20 price target.

9月20日,康泰鉑菲特分析師克里斯汀·克盧斯卡(Kristen Kluska)重申對adma biologics的超配評級,並維持20美元的目標價。

Cramer recommended buying Modine Manufacturing (NYSE:MOD). "It's just one of these great metal-bending companies," he added.

克雷默建議買入摩丁製造(紐交所:MOD)。他補充說:「這只是這些優秀金屬彎曲公司中的一家。」

On Sept. 24, DA Davidson analyst Matt Summerville maintained Modine Manufacturing with a Buy and raised the price target from $140 to $155.

9月24日,DA Davidson分析師馬特·薩默維爾(Matt Summerville)維持摩丁製造的買入評級,並將目標價從140美元上調至155美元。

Robinhood (NASDAQ:HOOD) is a buy, Cramer said.

羅賓漢(納斯達克:HOOD)是一個買入的選擇,克雷默表示。

On Oct. 8, Piper Sandler analyst Patrick Moley maintained Robinhood with an Overweight and maintained a $27 price target.

10月8日,派傑投資分析師帕特里克·莫利(Patrick Moley)維持羅賓漢的超配評級,並維持27美元的目標價。

Price Action:

價格行動:

  • Old Dominion shares gained 0.1% to settle at $194.59 on Thursday.
  • Micron shares gained 3.9% to close at $105.69.
  • American Tower shares fell 1.3% to close at $217.90 on Thursday.
  • Howmet Aerospace shares fell 1.5% to close at $102.10 during the session.
  • Modine Manufacturing shares fell 2.3% to settle at $130.95 on Thursday.
  • ADMA Biologics shares fell 16.3% to settle at $17.01.
  • Robinhood shares fell 0.6% to close at $25.50 on Thursday.
  • CVS shares gained 1.3% to close at $66.85 on Thursday.
  • Old Dominion股票漲了0.1%,週四收於194.59美元。
  • 美光科技股票上漲了3.9%,收於105.69美元。
  • 美國塔架股票下跌了1.3%,週四收於217.90美元。
  • howmet aerospace股票下跌了1.5%,本次交易收盤價爲102.10美元。
  • 摩丁製造股票下跌了2.3%,週四收於130.95美元。
  • adma biologics股票下跌了16.3%,週四收於17.01美元。
  • 羅賓漢股票下跌了0.6%,週四收於25.50美元。
  • 西維斯健康股票週四收盤漲1.3%,收於66.85美元。
  • Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
  • 兩隻醫療保健股票,正在在投資組合中引發重要變化

Image: Shutterstock

圖片:shutterstock

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論